Abstract
Objective: To evaluate the efficacy and side effects of different doses of erythromycin in patients with stable non-cystic fibrosis bronchiectasis (NCFB). Method: Altogether, 148 patients diagnosed with stable NCFB were enrolled in this study and randomly assigned to one of the following four treatment groups: Group A received erythromycin 250 mg/day; Group B received erythromycin 375 mg/day; Group C received erythromycin 500 mg/day; and Group D received a placebo. Each group consisted of 35 patients. The dataset comprised lung function data and computed tomography(CT), St. George’s Respiratory Questionnaire (SGRQ), modified Medical Research Council, bronchiectasis severity index(BSI), and E-FACED scores, which were collected before and at 6 months after treatment. These were subjected to a univariate analysis. Result: Groups C and D exhibited significant differences in forced expiratory volume in 1 second, forced vital capacity (FVC), quality of life, and CT Bhalla, BSI, and E-FACED scores (P < 0.05). Additionally, Groups B and D demonstrated significant differences in FVC and SGRQ, BSI, and EFACED scores (P < 0.05). Contrarily, Group A exhibited non-significant differences. Conclusion: The oral erythromycin regimen at a dose of 500 mg/day can improve the lung function and quality of life of stable NCFB patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call